Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.
|Data di pubblicazione:||2015|
|Titolo:||Mycophenolate mofetil in primary central nervous system vasculitis|
|Autori:||Salvarani, Carlo; Brown, Robert D; Christianson, Teresa J H; Huston, John; Giannini, Caterina; Miller, Dylan V; Muratore, Francesco; Hunder, Gene G|
|Digital Object Identifier (DOI):||10.1016/j.semarthrit.2015.02.008|
|Appare nelle tipologie:||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris